Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy - Wikidata - thesis-toulmin - TriplyDB

Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

http://www.wikidata.org/entity/Q28307991

about

Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?Next-generation prognostic assessment for diffuse large B-cell lymphoma Gene expression analysis in RA: towards personalized medicine Treatment of diffuse large B cell lymphoma Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era.Correlation of pretreatment 18F-FDG uptake with clinicopathological factors and prognosis in patients with newly diagnosed diffuse large B-cell lymphoma.Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update A microarray platform-independent classification tool for cell of origin class allows comparative analysis of gene expression in diffuse large B-cell lymphoma Utility of a simple prognostic stratification based on platelet counts and serum albumin levels in elderly patients with diffuse large B cell lymphoma.Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.Immunohistochemical and molecular characteristics with prognostic significance in diffuse large B-cell lymphoma.Molecular Testing of Lymphoproliferative Disorders: Current Status and Perspectives.MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy.Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab era.The histological classification of diffuse large B-cell lymphomas Aggressive B-cell lymphomas: how many categories do we need?Identification and validation of a two-gene expression index for subtype classification and prognosis in Diffuse Large B-Cell Lymphoma The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.Genetic lesions in diffuse large B-cell lymphomas Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma Machine Learning-based Classification of Diffuse Large B-cell Lymphoma Patients by Their Protein Expression Profiles.Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification Prognostic significance of peripheral monocytic myeloid-derived suppressor cells and monocytes in patients newly diagnosed with diffuse large b-cell lymphoma.Molecular profiling reveals prognostically significant subtypes of canine lymphoma.Non-Hodgkin lymphoma and GIST: molecular pathways and clinical expressions.The distinct clinical features and prognosis of the CD10⁺MUM1⁺ and CD10⁻Bcl6⁻MUM1⁻ diffuse large B-cell lymphoma.Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma.Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Con CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Pr Primary diffuse large B-cell lymphoma of the ascending colon.

P2860

Q24597424-A13E4715-3068-4482-99E2-1D8D70DC7AE2 Q26796428-82CA7B19-D893-46E9-A9F6-97A51406DCA7 Q26825706-965CA1C7-D2AB-4DB4-A472-C49EC544414C Q27006062-DA313F2D-4FE0-4EE1-9169-42EC69D9DFD8 Q27314782-EF0767C6-5EAD-4DAB-A391-C9043FE8C3AD Q27314809-185B1964-A865-485A-80C0-B9756CAA20B4 Q28078869-B3AB032D-2EB1-4D1E-8D2A-814F9B65DE6E Q30485971-6114D997-B542-42AA-B81F-51BFFDF4004E Q33435420-3A560098-8117-4CE6-ADCC-2D16169E39D2 Q33591789-37E8AF82-ACE8-4C8E-B46C-D2DD789837D2 Q33700531-97AF072F-D3FF-40A7-83EB-7B8D69A358B0 Q33729711-5FF2CC96-2B9E-46C3-BE5F-F316377DC3D9 Q34000188-4DEE05D8-0FCE-47F4-BC0E-46B66E9FB617 Q34292361-4750B88E-5714-4A7E-B4DA-943C1B9FECD3 Q34390837-57553E77-B9D8-4899-97C2-49245A5F469D Q34617849-4BF6CC86-3440-4FCB-9B3E-CA01A6D50F6B Q35193836-13C6F089-8B3F-4EF4-848E-E492FD0A55E2 Q35218051-EE8F8B8D-403F-4876-B18B-7CF58B94A5FA Q35527893-595EEFC4-10D1-4507-9145-5698A9B2AACE Q35569017-4BCD4690-4D78-4F01-85DF-2D992BFD5ED6 Q35606714-299B24EA-31E4-4C23-936A-0F96852CB584 Q35755485-A56BAA6D-5A34-45CD-97B7-D4F3DBFC41D4 Q35797583-A52D0E1F-541C-473D-884B-F8FBA90E76DE Q35930640-B156405E-E77B-4C84-AAF2-6CD1A76DDA84 Q35974341-3C5CBBE7-96A7-4FDB-8659-58DD5708AC6E Q36011142-DC9E1415-2FAF-4583-B49B-F7ADDE338392 Q36192439-D3B33962-6EDF-432B-9598-5DFB8CA466BA Q36249448-EA26A3E9-0422-42E9-9003-5D53260B5901 Q36263022-67034F1B-1906-488C-ACC7-392807EE30E2 Q36267666-0F22FF8A-B69C-4673-A2C0-F81E695F0556 Q36280547-7B7290D4-DE6E-456E-BF19-294C1E1DA9AB Q36317453-4DD9FE16-5522-4F79-8391-BCBF276239B2 Q36381346-2FA6EFEB-FA6D-4D79-871B-9AA0DD46994F Q36474669-DDE9E602-3838-4D8B-8E81-FFD2A87F093C Q36559885-11627FEA-D5E2-4869-909B-FB62FC8B0EDC Q36776444-93A2CA7F-1AD5-4F04-AC51-1D956AD76C74 Q36799606-8F1095E5-5793-4972-A15D-042698DD4E5F Q36979534-FD6D29F5-38B0-44A6-BD0A-B0786E4B7302 Q37006876-9655F961-92DF-4971-BBAA-9AB0A989E2A1 Q37034634-952FA295-4AA8-4C74-9958-64854356C932

P2860

Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

http://www.wikidata.org/entity/Q28307991

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Gene-expression profiling and ...... reated with immunochemotherapy

@ast

Gene-expression profiling and ...... reated with immunochemotherapy

@en

Gene-expression profiling and ...... reated with immunochemotherapy

@nl

type

label

Gene-expression profiling and ...... reated with immunochemotherapy

@ast

Gene-expression profiling and ...... reated with immunochemotherapy

@en

Gene-expression profiling and ...... reated with immunochemotherapy

@nl

prefLabel

Gene-expression profiling and ...... reated with immunochemotherapy

@ast

Gene-expression profiling and ...... reated with immunochemotherapy

@en

Gene-expression profiling and ...... reated with immunochemotherapy

@nl

P1433

Q28307991-3F56AD77-1D3D-4860-AF80-D2172987A17D

P1476

Q28307991-62067B13-283E-44AC-81F4-3C98D61D0ACE

P2093

Q28307991-074ACD6A-817E-4963-A8E1-251C03F830D5

Q28307991-0FEA3CA7-7C83-427D-ADB0-8FC6A9EAEB25

Q28307991-1E381654-A1BB-4404-8E56-DA89EA4B89CA

Q28307991-22EC97A3-7913-420E-8966-4FA3566042ED

Q28307991-281BAF26-E1B2-499F-B9A9-9E1E4BA9715A

Q28307991-3F1D5027-96B5-4D34-8574-751531BEFDB6

Q28307991-5CA5CDF2-2F2E-4C82-975B-02E6874F09EA

Q28307991-855C6A11-0AE4-473C-8984-C9B8DA90F034

Q28307991-8C531D8F-9AF6-4754-807A-2D1E5942AD11

Q28307991-900B9ACF-6E02-42A3-A103-201CB1C0DD89

P304

Q28307991-DB6ABDBE-AC8C-4845-9865-92FF5BEADDEA

P31

Q28307991-7F333DF8-AE89-4193-A0E6-EB085D453BEE

P3181

Q28307991-C5704AB5-C4FE-4A2B-A1C3-C209E4AC3EA6

P356

Q28307991-A555CCDE-8D17-4157-A4D2-22CD7DF4764D

P407

Q28307991-660D1C7D-ABF6-4673-9D09-4EFBEAD9218F

P433

Q28307991-8F153BA9-E2B2-4D05-8B5A-01EDC0D288FA

P478

Q28307991-D98F3C90-0677-49AB-B118-7344F86ACF12

P50

Q28307991-1900BFAC-6EC6-4D8B-8240-C3FE89698614

Q28307991-1D244554-E405-496C-85BD-DBC9776D8711

Q28307991-22EC8541-49DD-4199-AE6D-E1FCF0A18D99

Q28307991-7C55973A-F959-4A4F-BC61-FD6E55E36AC4

Q28307991-A2A2AEC4-5C56-4DDD-A9B6-668D822C07EC

P577

Q28307991-255573E0-7AFE-42F3-A791-FF3DE6945531

P5875

Q28307991-5E125C10-8E7B-4C9D-8D0B-D36391CB518A

P698

Q28307991-E74E1323-90F9-40A0-B8C2-6DAC32E6AB47

P921

Q28307991-4163237E-C690-430A-8D5B-16882A92AC90

Q28307991-F3F8C175-094F-403B-AEA3-A85D107D5D1A

P3181

P356

BLOOD-2010-12-322362

P1433

P1476

Gene-expression profiling and ...... reated with immunochemotherapy

@en

P2093

Adriana García-Herrera

http://www.w3.org/2001/XMLSchema#string

Alejandra Martínez-Trillos

http://www.w3.org/2001/XMLSchema#string

Alexandra Valera

http://www.w3.org/2001/XMLSchema#string

Antonio Martínez

http://www.w3.org/2001/XMLSchema#string

Armando López-Guillermo

http://www.w3.org/2001/XMLSchema#string

Eva Giné

http://www.w3.org/2001/XMLSchema#string

Fina Climent

http://www.w3.org/2001/XMLSchema#string

Grup per l'Estudi dels Limfomes de Catalunya I Balears (GELCAB)

http://www.w3.org/2001/XMLSchema#string

José L Mate

http://www.w3.org/2001/XMLSchema#string

Juan M Sancho

http://www.w3.org/2001/XMLSchema#string

P304

4836-4843

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

289348

http://www.w3.org/2001/XMLSchema#string

P356

10.1182/BLOOD-2010-12-322362

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

Leonor Arenillas

Gonzalo Gutiérrez-García

Eva Gonzalez-Barca

P577

2011-03-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50867917

http://www.w3.org/2001/XMLSchema#string

P698

21441466

http://www.w3.org/2001/XMLSchema#string

P921